In Singapore on February 4, 2026, NeuroAiD™II received acknowledgment due to its strong clinical evidence and distinctive formulation. The recognition also emphasized the rigor of manufacturing, reproducibility, and quality control of NeuroAiD™II, underscoring its reliability and value in aiding support.